Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01746810 · ClinicalTrials.gov registry record · Phase 1
IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01746810: Clinical Trial Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
NCT01746810 is a Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01746810, a Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with ablation therapy in treating patients with non-small cell lung cancer or lung metastases. Ablation therapy, such as radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Ablation therapy, such as microwave ablation kills tumor cells by heating them to several degrees above normal body temperature. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving ablation therapy together with stereotactic body radiation therapy may kill more tumor cells.
Primary Outcome
The MTD will be defined as the highest dose level where less than or equal to 33% patients incurred a dose-limiting toxicity (DLT). A DLT will be defined as an acute (within 30 days) or subacute (31-90 days) irreversible grade 3 or any grade 4-5 toxicity (using National Cancer Institute \[NCI\]-Common Toxicity Criteria \[CTC\] version 4.0 criteria) that is possibly, probably, and definitely attributed to the therapy.
Interventions
- RADIATION Stereotactic body RT and IRGA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-10-13 |
| Phase | Phase 1 |
Why NCT01746810 stopped before completion
NCT01746810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Stereotactic body RT and IRGA is the first listed.
NCT01746810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01746810 about?
NCT01746810 is a clinical study titled "IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors". This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with ablation therapy in treating patients with non-small cell lung cancer or lung metastases. Ablation therapy, such as radiofrequency ablation uses a high-frequency, electric curren...
What is the current status of trial NCT01746810?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-07. Estimated completion is 2015-10-13.
What interventions are being tested in trial NCT01746810?
The interventions under investigation include: Stereotactic body RT and IRGA (RADIATION).
Who is sponsoring clinical trial NCT01746810?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01746810's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia